Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer

Oncology Reports

Volumn 31, Issue 6, 2014, Pages 2482-2492

  Ma, Liang ^a   Sato, Fuminori ^a   Sato, Ryuta ^a   Matsubara, Takanori ^b   Hirai, Kenichi ^a   Yamasaki, Mutsushi ^a   Shin, Toshitaka ^a   Shimada, Tatsuo ^a   Nomura, Takeo ^c   Mori, Kenichi ^a   Sumino, Yasuhiro ^a   Mimata, Hiromitsu ^a  

^a OITA UNIVERSITY   (Japan)

^b Nakamura Hospital   (Japan)

^c Tsurumi Hospital   (Japan)

Author keywords

Akt; Bladder cancer; Chemotherapy; HSP70; HSP90

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CISPLATIN; DOCETAXEL; GEMCITABINE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; PIFITHRIN MU; PROTEIN BAD; PROTEIN KINASE B; TANESPIMYCIN; UNCLASSIFIED DRUG; BENZOQUINONE DERIVATIVE; MACROCYCLIC LACTAM;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CASPASE ASSAY; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

APOPTOSIS; BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84902169156     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3132     Document Type: Article

References (46)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet 374: 239-249, 2009.
3. Mitra AP, Datar RH and Cote RJ: Molecular staging of bladder cancer. BJU Int 96: 7-12, 2005. (Pubitemid 40942859)
4. Bambury RM and Rosenberg JE: Advanced urothelial carcinoma: overcoming treatment resistance through novel treatment approaches. Front Pharmacol 4: 3, 2013.
5. Luo T, Yu J, Nguyen J, et al: Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers. Proc Natl Acad Sci USA 109: 10175-10180, 2012.
6. Drayton RM and Catto JW: Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev Anticancer Ther 12: 271-281, 2012.
7. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352: 2302-2313, 2005. (Pubitemid 40740554)
8. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004. (Pubitemid 39315317)
9. Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016-3024, 2003. (Pubitemid 46606280)
10. McKiernan JM, Masson P, Murphy AM, et al: Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24: 3075-3080, 2006.
11. de Wit R, Kruit WH, Stoter G, de Boer M, Kerger J and Verweij J: Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 78: 1342-1345, 1998.
12. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI and Bajorin DF: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15: 1853-1857, 1997. (Pubitemid 27209514)
13. Toschi L, Finocchiaro G, Bartolini S, Gioia V and Cappuzzo F: Role of gemcitabine in cancer therapy. Future Oncol 1: 7-17, 2005.
14. Bellmunt J, Albiol S, de Olano AR, Pujadas J, Maroto P; Spanish Oncology Genitourinary Group (SOGUG): Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann Oncol 17 (Suppl 5): v113-v117, 2006. (Pubitemid 43985219)
15. Cognetti F, Ruggeri EM, Felici A, et al: Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 23: 695-700, 2012.
16. Kim JJ: Recent advances in treatment of advanced urothelial carcinoma. Curr Urol Rep 13: 147-152, 2012.
17. Neri B, Vannini L, Giordano C, et al: Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study. Anticancer Drugs 18: 1207-1211, 2007. (Pubitemid 47480746)
18. Boukovinas I, Androulakis N, Vamvakas L, et al: Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group. Ann Oncol 17: 1687-1692, 2006. (Pubitemid 44680890)
19. Maloney A and Workman P: HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2: 3-24, 2002. (Pubitemid 34462457)
20. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC and Burrows FJ: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410, 2003. (Pubitemid 37187270)
21. Schulte TW and Neckers LM: The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42: 273-279, 1998. (Pubitemid 28393843)
22. Karkoulis PK, Stravopodis DJ, Margaritis LH and Voutsinas GE: 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer 10: 481, 2010.
23. Barluenga S, Fontaine JG, Wang C, et al: Inhibition of HSP90 with pochoximes: SAR and structure-based insights. Chembiochem 10: 2753-2759, 2009.
24. Barluenga S, Wang C, Fontaine JG, et al: Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor. Angew Chem Int Ed Engl 47: 4432-4435, 2008.
25. Solit DB, Osman I, Polsky D, et al: Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 14: 8302-8307, 2008.
26. Weng SH, Tseng SC, Huang YC, Chen HJ and Lin YW: Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells. Biochem Pharmacol 84: 126-136, 2012.
27. Vasilevskaya IA, Rakitina TV and O'Dwyer PJ: Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol 65: 235-243, 2004. (Pubitemid 38113905)
28. Solit DB, Basso AD, Olshen AB, Scher HI and Rosen N: Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 63: 2139-2144, 2003. (Pubitemid 36538618)
29. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO and Karnitz LM: Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 278: 52572-52577, 2003. (Pubitemid 38035854)
30. Ghoshal S, Rao I, Earp JC, Jusko WJ and Wetzler M: Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer Chemother Pharmacol 66: 681-689, 2010.
31. Wang RE: Targeting heat shock proteins 70/90 and proteasome for cancer therapy. Curr Med Chem 18: 4250-4264, 2011.
32. Leu JI, Pimkina J, Frank A, Murphy ME and George DL: A small molecule inhibitor of inducible heat shock protein 70. Mol Cell 36: 15-27, 2009.
33. Newman B, Liu Y, Lee HF, Sun D and Wang Y: HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells. Cancer Res 72: 4551-4561, 2012.
34. Zhang H and Burrows F: Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82: 488-499, 2004. (Pubitemid 39149859)
35. Yoshida S, Koga F, Tatokoro M, et al: Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle 10: 4291-4299, 2011.
36. Tatokoro M, Koga F, Yoshida S, Kawakami S, Fujii Y, Neckers L and Kihara K: Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer 131: 987-996, 2012.
37. Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M and Lin J: Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 20: 407-416, 2000. (Pubitemid 30189787)
38. Li X, Luo R, Jiang R, Meng X, Wu X, Zhang S and Hua W: The role of the Hsp90/Akt pathway in myocardial calpain-induced caspase-3 activation and apoptosis during sepsis. BMC Cardiovasc Disord 13: 8, 2013.
39. Evans CG, Chang L and Gestwicki JE: Heat shock protein 70 (Hsp70) as an emerging drug target. J Med Chem 53: 4585-4602, 2010.
40. Pocaly M, Lagarde V, Etienne G, et al: Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia 21: 93-101, 2007. (Pubitemid 44921840)
41. Gabai VL, Budagova KR and Sherman MY: Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene 24: 3328-3338, 2005. (Pubitemid 40695114)
42. Guo F, Rocha K, Bali P, et al: Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 65: 10536-10544, 2005. (Pubitemid 41743748)
43. Håvik B and Bramham CR: Additive viability-loss following hsp70/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines. Oncol Rep 17: 1501-1510, 2007.
44. Gao T and Newton AC: The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinase C. J Biol Chem 277: 31585-31592, 2002. (Pubitemid 34968961)
45. Liu H, Zhang T, Chen R, McConkey DJ, Ward JF and Curley SA: Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. J Surg Res 176: 147-153, 2012.
46. Pommier Y, Sordet O, Antony S, Hayward RL and Kohn KW: Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23: 2934-2949, 2004. (Pubitemid 38638854)